Chemomab Therapeutics Ltd DRC
$ 1.55
-4.32%
19 May - close price
- Market Cap 11,664,600 USD
- Current Price $ 1.55
- High / Low $ 1.68 / 1.53
- Stock P/E N/A
- Book Value 1.49
- EPS -1.44
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.71 %
- 52 Week High 5.77
- 52 Week Low 1.35
About
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
Analyst Target Price
$15.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-19 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-03 | 2024-11-14 | 2024-08-21 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-14 |
| Reported EPS | -0.003 | -0.003 | -0.004 | -0.016 | -0.007 | -0.008 | -0.01 | -0.26 | -0.2753 | -0.2654 | -0.02 | -0.036 |
| Estimated EPS | 0 | -0.01 | -0.005 | -0.1 | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 | -0.02 | -0.03 |
| Surprise | -0.003 | 0.007 | 0.001 | 0.084 | 0.003 | 0.002 | 0 | -0.25 | -0.2453 | -0.2454 | 0 | -0.006 |
| Surprise Percentage | None% | 70% | 20% | 84% | 30% | 20% | 0% | -2500% | -817.6667% | -1227% | 0% | -20% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMMB
2026-05-19 13:09:25
Chemomab Therapeutics Ltd. is poised to present its lead drug candidate, Nebokitug, at a European medical congress. Nebokitug is a first-in-class monoclonal antibody targeting CCL24, a protein involved in inflammatory and fibrotic pathways central to primary sclerosing cholangitis and other fibro-inflammatory diseases. The company aims for Nebokitug to potentially become the first approved therapy for primary sclerosing cholangitis.
2026-05-15 03:39:54
Chemomab Therapeutics reported a first-quarter loss per share of 0.3 cents, as indicated by the >CMMB stock ticker. This brief financial update provides key information on the company's recent performance.
2026-05-14 19:09:09
Chemomab Therapeutics announced its Q1 2026 financial results, reporting a net loss of $1.8 million and cash reserves to fund operations through Q1 2027. The company highlighted new clinical data for nebokitug, showing promising effects in treating primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). This data suggests nebokitug could be the first FDA-approved disease-modifying treatment for PSC, with plans for a Phase 3 trial underway.
2026-05-14 11:40:06
Chemomab Therapeutics reported a narrowed net loss of $1.77 million in Q1 2026, down from $3.32 million year-over-year, primarily due to reduced operating expenses. The company also highlighted new clinical data for its lead antibody, nebokitug, in primary sclerosing cholangitis (PSC) and PSC with co-existing inflammatory bowel disease (IBD), while advancing partnering options for the drug. Cash and cash equivalents stood at $8.04 million, expected to fund operations through Q1 2027.
2026-05-14 11:40:06
Chemomab Therapeutics announced its Q1 2026 financial results and provided a corporate update, highlighting productive discussions with potential strategic partners and new clinical data. The company presented new analyses from its nebokitug Phase 2 SPRING trial at Digestive Disease Week 2026 and upcoming EASL Congress presentations, further confirming nebokitug's potential in primary sclerosing cholangitis (PSC) and suggesting additional benefits for PSC patients with co-existing inflammatory bowel disease (IBD). Financially, Chemomab reported $8.0 million in cash, a net loss of $1.8 million, and expects its current liquidity to fund operations through Q1 2027.
2026-05-08 12:39:23
Chemomab Therapeutics (CMMB) shareholders approved key corporate governance items and authorized an increase in the company's authorized share capital at their May 5, 2026 meeting. The resolutions included re-electing directors, endorsing an updated compensation policy, and re-appointing Somekh Chaikin as the independent public accounting firm. Despite these approvals, TipRanks' AI Analyst "Spark" rates CMMB as Neutral due to weak financial fundamentals and a technically weak price trend.
